文献速递心力衰竭与心肌病

SGLT2抑制剂对癌症合并糖尿病患者心衰与死亡率的影响

Impact of sodium-glucose cotransporter-2 inhibitors on heart failure and mortality in patients with cancer.
PubMed 文献 · Heart · 2023-02-23

这项回顾性倾向评分匹配队列研究纳入2010至2021年确诊癌症的成人2型糖尿病患者,将878例SGLT2i使用者与非使用者匹配。中位随访18.8个月,SGLT2i与心衰住院风险降低72%相关,且2年总生存率更高,严重不良事件风险相似。

要点

  • SGLT2i与癌症合并糖尿病患者心衰住院风险降低72%相关。
  • SGLT2i使用者2年总生存率85.3%,高于非使用者的63.0%。
  • 低血糖和脓毒症等严重不良事件风险两组相似。

核心结论

  • 在癌症合并糖尿病的患者中,使用SGLT2i与较低的突发心衰住院率和延长的总生存期相关。

研究设计与样本

  • 回顾性倾向评分匹配队列研究,纳入2010年1月至2021年12月确诊癌症的成人2型糖尿病患者,从8640例中匹配878例SGLT2i使用者与878例非使用者。

主要发现

  • 中位随访18.8个月,SGLT2i使用者突发心衰住院率为2.92/1000患者年,非使用者为8.95/1000患者年(p=0.018)。
  • Cox回归显示SGLT2i与心衰住院风险降低72%相关(HR 0.28,95%CI 0.11-0.77,p=0.013)。
  • 竞争风险回归显示SGLT2i与心衰住院风险降低相关(子分布HR 0.32,95%CI 0.12-0.84,p=0.021)。
  • SGLT2i使用者2年总生存率为85.3%,非使用者为63.0%(p<0.001)。
  • 低血糖和脓毒症等严重不良事件风险两组相似。

临床怎么用

  • 对于癌症合并2型糖尿病的患者,可考虑使用SGLT2i以降低心衰住院风险并改善生存,但需结合个体情况评估。

局限性

  • 本研究为回顾性队列设计,可能存在残余混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) reduce heart failure (HF) in at-risk patients and may possess antitumour effects. We examined the effect of SGLT2i on HF and mortality among patients with cancer and diabetes. METHODS: This was a retrospective propensity score-matched cohort study involving adult patients with type 2 diabetes mellitus diagnosed with cancer between January 2010 and December 2021. The primary outcomes were hospitalisation for incident HF and all-cause mortality. The secondary outcomes were serious adverse events associated with SGLT2i. RESULTS: From a total of 8640 patients, 878 SGLT2i recipients were matched to non-recipients. During a median follow-up of 18.8 months, SGLT2i recipients had a threefold lower rate of hospitalisation for incident HF compared with non-SGLT2i recipients (2.92 vs 8.95 per 1000 patient-years, p=0.018). In Cox regression and competing regression models, SGLT2i were associated with a 72% reduction in the risk of hospitalisation for HF (HR 0.28 (95% CI: 0.11 to 0.77), p=0.013; subdistribution HR 0.32 (95% CI: 0.12 to 0.84), p=0.021). The use of SGLT2i was also associated with a higher overall survival (85.3% vs 63.0% at 2 years, p<0.001). The risk of serious adverse events such as hypoglycaemia and sepsis was similar between the two groups. CONCLUSIONS: The use of SGLT2i was associated with a lower rate of incident HF and prolonged overall survival in patients with cancer with diabetes mellitus.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Chiang, Chiang, Chiang, et al. Impact of sodium-glucose cotransporter-2 inhibitors on heart failure and mortality in patients with cancer. Heart. 2023. PMID: 36351793. doi:10.1136/heartjnl-2022-321545

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。